Cell Press Reviews: Cancer Therapeutics

Cell Press Reviews: Cancer Therapeutics informs, inspires, and connects cancer researchers at all stages in their careers with timely, comprehensive reviews written by leaders in the field and curated by Cell Press editors. The publicatio offers a broad view of some of the most compelling topics in cancer therapeutics including:

Genetic approaches for personal oncologyTargeting epigenetic dysregulation and protein interaction networksVaccines and antibodies in cancer immunotherapyTumor heterogeneity and chemotherapy resistanceTumor associated macrophages in anticancer treatment

Contributions come from leading voices in the field, including: - Daniel A. Haber, Director of Massachusetts General Hospital Cancer Center and Professor at Harvard Medical School - Tony Kouzarides, Professor at the University of Cambridge, Deputy Director of the Wellcome Trust/Cancer Research UK Gurdon Institute, and a founder of the cancer drug discovery company Chroma Therapeutics - Charles L. Sawyers, Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, President of the American Association for Cancer Research, member of the presidentially appointed National Cancer Advisory Board, and recipient of the 2013 Breakthrough Prize in Life Sciences

Cell Press Reviews: Cancer Therapeutics is part of the Cell Press Reviews series, which features reviews published in Cell Press primary research and Trends reviews journals.

Provides timely, comprehensive articles on a wide range of topics in cancer therapeuticsOffers insight from experts on genetic, molecular, and cellular aspects of cancer therapyFeatures reviews on basic science advances translated into drug discovery and therapeutic approachesIncludes articles originally published in Cell, Cancer Cell, Trends in Genetics, Trends in Molecular Medicine, and Trends in Pharmacological Sciences

1) The evolving war on cancer; Daniel A. Haber, Nathanael S. Gray and Jose Baselga; Cell 2) Can we deconstruct cancer, one patient at a time? C. Anthony Blau and Effie Liakopoulou; Trends in Genetics 3) The genetic basis for cancer treatment decisions; Janet E. Dancey, Philippe L. Bedard, Nicole Onetto and Thomas J. Hudson; Cell 4) Cancer epigenetics: From mechanism to therapy; Mark A. Dawson and Tony Kouzarides; Cell 5) Converting cancer therapies into cures: Lessons from infectious diseases; Michael S. Glickman and Charles L. Sawyers; Cell 6) Antibody-based immunotherapy of cancer; Louis M. Weiner, Joseph C. Murray and Casey W. Shuptrine; Cell 7) Macrophage regulation of tumor responses to anticancer therapies; Michele De Palma and Claire E. Lewis; Cancer Cell 8) Recombinant viral vaccines for cancer; Ryan Cawood, Thomas Hills, Suet Ling Wong, Aliaa A. Alamoudi, Storm Beadle, Kerry D. Fisher and Leonard W. Seymour; Trends in Molecular Medicine 9) Dynamics of targeted cancer therapy; Ivana Bozic, Benjamin Allen and Martin A. Nowak; Trends in Molecular Medicine 10) Targeting protein–protein interactions as an anticancer strategy; Andrei A. Ivanov, Fadlo R. Khuri and Haian Fu; Trends in Pharmacological Sciences 11) Targeting the RAS pathway in melanoma; Zhenyu Ji, Keith T. Flaherty and Hensin Tsao; Trends in Molecular Medicine 12) Targeting tumor cell motility as a strategy against invasion and metastasis; Alan Wells, Jelena Grahovac, Sarah Wheeler, Bo Ma and Douglas Lauffenburger; Trends in Pharmacological Sciences 13) The Valley of Death in anticancer drug development: a reassessment; David J. Adams; Trends in Pharmacological Sciences 14) Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects; Arian Emami Riedmaier, Pascale Fisel, Anne T. Nies, Elke Schaeffeler and Matthias Schwab; Trends in Pharmacological Sciences 15) Curing APL through PML/RARA degradation by As2O3; Valerie Lallemand-Breitenbach, Jun Zhu, Zhu Chen and Hugues de Thé; Trends in Molecular Medicine 16) A snapshot of chemoresistance to PARP inhibitors; Alberto Chiarugi; Trends in Pharmacological Sciences